Quantum BioPharma hits midpoint in mass general imaging study for multiple sclerosis

Quantum BioPharma (NASDAQ:QNTM) has reached the halfway enrollment mark in its collaborative clinical study with Massachusetts General Hospital (MGH), yielding encouraging preliminary imaging data.

The trial is designed to validate a novel positron emission tomography (PET) imaging technique capable of directly assessing demyelinated neurons with intact axons.

If successful, the platform could establish a quantitative method to track demyelination and repair in multiple sclerosis (MS) patients, a metric that remains an unmet need in neurodegenerative research.

The evaluation centers on a specialized PET tracer developed by investigators at MGH and Harvard Medical School.

Preliminary analysis from the first cohort of participants, imaged using advanced PET/MR and total-body PET platforms, showed robust signals in acute MS lesions alongside potential sensitivity to gray matter lesions.

Quantum intends to use this validated biomarker platform to generate precise, real-time measurements of therapeutic response for its own investigational pipeline.

The imaging approach is expected to support clinical tracking for Lucid-MS (Lucid-21-302), Quantum’s first-in-class small molecule designed to inhibit demyelination by targeting the PAD2 enzyme.

The company previously completed Phase 1 trials demonstrating a favorable safety profile for the candidate and submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration in March 2026 to initiate Phase 2 testing.